Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Sun Pharmaceutical pursued an acquisition in a quarterly results development for Q2FY27.
· ET Stocks, Economic Times Markets
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Key facts
- Period
- Q2FY27
The analysis
Sun Pharmaceutical reported Rs 1,989 crore for Q2FY27, with movement of 36% and 11.8% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹1,777.70, and has returned -11.2% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Sun Pharmaceutical is running 10.3 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Sun Pharmaceutical (SUNPHARMA), in Pharma & Healthcare.
- Over three months: Sun Pharmaceutical -11.2% against Pharma & Healthcare -0.9% (10.3 points behind).
- Trading well above normal today: Sun Pharmaceutical at 3.4 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Sun PharmaceuticalSUNPHARMA · Pharma & Healthcare | ₹1,777.70 | +0.9% | -2.1% | -11.2% | -11.2% | 3.4× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sun Pharmaceutical
Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell